Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Income from Continuing Operations (2016 - 2025)

Historic Income from Continuing Operations for Ligand Pharmaceuticals (LGND) over the last 16 years, with Q3 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Income from Continuing Operations rose 173515.06% to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year increase of 737.56%. This contributed to the annual value of -$4.0 million for FY2024, which is 10749.18% down from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Income from Continuing Operations stood at $117.3 million, which was up 173515.06% from $4.8 million recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Income from Continuing Operations high stood at $117.3 million for Q3 2025, and its period low was -$51.9 million during Q2 2024.
  • For the 5-year period, Ligand Pharmaceuticals' Income from Continuing Operations averaged around $10.6 million, with its median value being $9.6 million (2022).
  • As far as peak fluctuations go, Ligand Pharmaceuticals' Income from Continuing Operations crashed by 236685.59% in 2024, and later soared by 173515.06% in 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' Income from Continuing Operations (Quarter) stood at $13.8 million in 2021, then plummeted by 205.33% to -$14.5 million in 2022, then surged by 225.14% to $18.2 million in 2023, then tumbled by 270.93% to -$31.1 million in 2024, then soared by 477.23% to $117.3 million in 2025.
  • Its last three reported values are $117.3 million in Q3 2025, $4.8 million for Q2 2025, and -$42.5 million during Q1 2025.